30-Minutes Sessions

Session 1 | LifeSciences@Work
Chair: Pedro Tetteroo
Panel members:
Renske Landeweert, ClearDetections
Sigi Neerken, Polaris/Philips
Stefan Braam, Pluriomics
Suzan Commandeur, Biomimiq

Start-up support for life sciences ventures. Find out how we can help realise your entrepreneurial ambitions.

Session 2 | Innovative Medical Devices Initiatives
NL
Matthijs Oudkerk, Clinical/care scientific leader and
Vinod Subramaniam, Technical scientific leader
Centre for Medical Imaging North East Netherlands (CMI-NEN)

Introducing a new ZonMw programme focusing on
the Dutch infrastructure in the area of medical devices.

Session 3 | Science for Society - Societal Valorisation in the Making
Daan Schuurbiers, De Proeffabriek
Isa Houwink, General practitioner

The CSG Centre for Society and the Life Sciences presents two inspiring highlights in societal valorisation.

Session 4 | Dutch Technology Centre for Life Sciences (DTL)
Ruben Kok, Executive Director Netherlands Bioinformatics Centre
Ton Rijnders, Director TIPharma

A new initiative that offers demand-driven technology development for the life sciences field.

Session 5 | The Making of the Prosensa Harvard Style Business Case
Fred van Eenennaam, The Decision Group
Hans Schikan, Prosensa
Roald van Leeuwen, The Decision Group

Currently a consortium consisting of NGI, LUMC, LSH, Prosensa, PGGM, Leiden University and The Decision Group are developing the Prosensa case.

The objective of the case is to demonstrate a success story of the Dutch biotech cluster which can be used for teaching at universities and for promotional activities within the Netherlands or abroad. The 30-Minutes session will briefly show the process of building the case, accompanied with a discussion on dilemma's faced in the development of a biotech company.

Session 6 | Drug Development in Oss:
MSD and Life Sciences Park
Mirjam Mol-Arts, Vice President, Lead MSD Development Center Oss

MSD is the largest pharmaceutical company in the Netherlands. The MSD Development Center in Oss (DCO) supports MSD's need for product development activities, particularly for the emerging markets. The DCO is also involved in Product Value Enhancement and it supports MSD's early phase clinical research in multiple therapeutic areas.

Life Sciences Park in Oss, initiated by MSD, is the planned new center of open innovation for starting and existing entrepreneurs, a dynamic setting of cutting-edge infrastructure for research and production which is scheduled to be launched on January 1, 2012.